Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of mortality in sarcoidosis: a nationwide cohort study from the SARCOGEAS registry.

Clinical and experimental rheumatology·2026
Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026
Same author

Incidence of Drug-Induced Liver Injury in the Urban Primary Care Setting.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

AI Integration in Spanish Undergraduate Medical Education: National Cross-Sectional Study.

JMIR medical education·2026
Same author

Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL).

PloS one·2026
Same author

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal of clinical epidemiology·2026

Related Experiment Video

Updated: Jun 13, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Targeted therapy for systemic sclerosis: how close are we?

Manuel Ramos-Casals1, Vicent Fonollosa-Pla, Pilar Brito-Zerón

  • 1Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain. mramos@clinic.ub.es

Nature Reviews. Rheumatology
|April 14, 2010
PubMed
Summary

Systemic sclerosis treatment remains challenging, with many tested drugs proving ineffective. Future research focuses on targeted therapies and combination treatments for better patient outcomes.

Related Experiment Videos

Last Updated: Jun 13, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic sclerosis is a complex autoimmune disease with limited effective therapeutic options.
  • Despite extensive drug testing, no treatment has demonstrated consistent efficacy.
  • Recent years have seen advancements in identifying new therapeutic targets and developing selective drugs.

Purpose of the Study:

  • To review the current landscape of systemic sclerosis treatment.
  • To discuss emerging therapeutic strategies and their outcomes.
  • To highlight future directions in systemic sclerosis drug development.

Main Methods:

  • Review of recent literature on systemic sclerosis pathogenesis and therapeutics.
  • Analysis of clinical trial outcomes for novel drug classes.
  • Evaluation of targeted therapies including endothelin antagonists and tyrosine kinase inhibitors.
  • Exploration of antifibrotic agents targeting transforming growth factor beta pathways.

Main Results:

  • Established drugs have shown limited efficacy in systemic sclerosis.
  • Newer agents like endothelin antagonists are in use, while others like tyrosine kinase inhibitors show promise.
  • Trials of antifibrotic drugs (e.g., statins, antidiabetics) targeting transforming growth factor beta have yielded negative results.
  • Research into disease-specific therapies targeting distinct biological pathways is ongoing.

Conclusions:

  • Systemic sclerosis management remains complex, necessitating continued research into novel therapeutic targets.
  • Selective drugs and targeted pathways represent a significant shift in treatment strategy.
  • Future treatment may involve combination therapies for improved efficacy over current monotherapies.